Assessing allergenicity of GM plants: new EFSA guidance provides advice
EFSA has published supplementary guidance on allergenicity to further strengthen risk assessment of genetically modified (GM) plants.
The document considers new scientific and regulatory developments, complementing recommendations in existing guidance and regulations.
What are the key points?
The new guidance relates to three particular areas.
Non-IgE-mediated adverse immune reactions to food comprise a large group of diseases, mostly occurring during childhood. Celiac disease is currently the best characterised of these diseases and therefore the only condition of this type covered by the guidance. The guidance provides detailed advice on how to assess the risk of novel proteins in GM plants causing celiac disease.
In vitro digestibility tests provide valuable information on how a newly created protein in a GM plant behaves during digestion, an important part of the overall safety assessment. The new guidance suggests refinements in the way current in vitro tests are conducted and proposes to evaluate their added value during a two-year interim period.
The assessment of endogenous allergenicity ensures the genetic modification does not adversely affect the levels of existing allergens in the GM plant compared to its conventional counterpart. This guidance document provides detailed additional information on how to address this requirement.
Successful conclusion of pilot project
The publication of this guidance document brings a two year-long pilot project to a successful conclusion. EFSA’s aim was to increase engagement with stakeholders in its scientific processes as part of the Open EFSA initiative.
An eight-member focus group acted as the consultative body throughout the development of this document. All parties involved agreed that the scientific process benefited from this inclusive approach.
- Guidance on allergenicity assessment of genetically modified plants
- Outcome of the public consultation on the draft guidance on allergenicity assessment of genetically modified plants
Notes to editors:
Immunoglobulin E (IgE) is a type of antibody produced by the immune system in response to an allergen. Non-IgE mediated immune reactions are those in which other mediators in the body are involved.
Latest News from
EC opens in-depth investigation into proposed acquisition of Monsanto by Bayer23/08/2017 11:20:00
The EC has opened an in-depth investigation to assess the proposed acquisition of Monsanto by Bayer under the EU Merger Regulation. The EC has concerns that the merger may reduce competition in areas such as pesticides, seeds and traits.
Tick and flea control agent Bravecto continues to be acceptably safe to use18/08/2017 13:20:00
New adverse reaction to be included in package leaflet
Trend of converging working time across 28 EU Member States has stalled18/08/2017 12:20:00
The difference in working time between workers in the 28 EU Member States remains large and is especially marked between the ‘older’ 15 EU Member States and the 13 new Member States that joined the EU since 2004, according to new research from Eurofound.
European Solidarity Corps: First volunteers in Italy to help rebuild earthquake-hit regions18/08/2017 11:20:00
The first group of European Solidarity Corps volunteers is arriving in Norcia, Italy, to help with the ongoing efforts to repair damage and rebuild social services for the local community affected by the severe earthquakes that hit the region a year ago.